Anish Bhatnagar 4

Accession 0001614821-26-000001

CIK 0001484565other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 6:00 PM ET

Size

8.0 KB

Accession

0001614821-26-000001

AI-generated summary of this filing

Updated Jan 23, 2026

Soleno (SLNO) CEO Anish Bhatnagar Receives RSU Award

What Happened

Anish Bhatnagar, CEO of Soleno Therapeutics (SLNO), received equity awards on 2026-01-21: 114,200 restricted stock units (RSUs) and 131,400 RSUs (reported as a derivative award). Both awards were granted at $0.00 (no cash exchanged), for a total of 245,600 RSUs awarded.
These are awards (code A on the Form 4). One set (114,200 RSUs) is subject to a single vesting date; the other set is described as RSUs subject to applicable vesting schedules and conditions.

Key Details

Transaction date: 2026-01-21; filing date: 2026-01-23 (filed timely).
Grant price: $0.00 per RSU; total immediate cash value reported: $0.
Total RSUs granted: 114,200 + 131,400 = 245,600 RSUs.
Shares owned after transaction: not specified in the provided filing excerpt.
Footnotes of note:
- F1: The 114,200 RSUs vest 100% on December 15, 2027, contingent on continued service.
- F2: The 131,400 RSUs are RSUs subject to the applicable vesting schedule and conditions of each RSU.
- F3: Separately, certain option awards held by the reporting person vest 1/48th monthly beginning Feb 1, 2026 (this describes existing option vesting, not the new RSU grants).
Transaction type: Award/Grant (A). These are contingent RSUs, not immediate shares.

Context

RSUs are contingent rights to receive common stock upon vesting; they do not represent immediate ownership or a cash purchase signal. Vesting schedules determine when the CEO will actually receive shares.
This filing reports newly granted compensation equity to the CEO and was filed within the SEC’s required timeframe.

Form 4

Period: 2026-01-21

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Award
Common Stock
[F1][F2]
2026-01-21+114,200→ 583,656 total
Award
Employee stock option (right to buy)
[F3]
2026-01-21+131,400→ 131,400 total
Exercise: $43.65Exp: 2036-01-21→ Common Stock (131,400 underlying)

Footnotes (3)

[F1]These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.
[F2]Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
[F3]1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Signature

/s/ Anish Bhatnagar|2026-01-23

1 file

SOLENO THERAPEUTICS INC

CIK 0001484565

Entity typeother